Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancer

Biomedicine and Pharmacotherapy

Volumn 78, Issue , 2016, Pages 116-120

  Luo, Hong Wei ^a   Chen, Qing Biao ^a   Wan, Yue Ping ^a   Chen, Guan Xing ^b   Zhuo, Yang Jia ^a   Cai, Zhi Duan ^a   Luo, Zheng ^c   Han, Zhao Dong ^b   Liang, Yu Xiang ^b   Zhong, Wei De ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Biochemical recurrence free survival; Prostate cancer; Protein regulator of cytokinesis 1

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; PROTEIN REGULATOR OF CYTOKINESIS 1; REGULATOR PROTEIN; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; PRC1 PROTEIN, HUMAN;

AGED; ARTICLE; BIOCHEMICAL RECURRENCE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SURVIVAL TIME; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PROSTATE TUMOR; TUMOR INVASION; TUMOR RECURRENCE;

AGED; CELL CYCLE PROTEINS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS;

EID: 84958594746     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.01.004     Document Type: Article

References (20)

1. Attard G., Parker C., Eeles R.A., Schröder F., Tomlins S.A., Tannock I., Drake C.G., de Bono J.S. Prostate cancer. Lancet 2015, (in press).
2. Crawford E.D., Higano C.S., Shore N.D., Hussain M., Petrylak D.P. Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J. Urol. 2015, 194(6):1537-1547.
3. Marshall S., Taneja S. Focal therapy for prostate cancer: the current status. Prostate Int. 2015, 3:35-41.
4. Saad F., Fizazi K.S. Androgen deprivation therapy and secondary hormone therapy in the management of hormone-sensitive and castration resistant prostate cancer. Urology 2015, 86(5):852-861.
5. Khemlina G., Ikeda S., Kurzrock R. Molecular landscape of prostate cancer: implications for current clinical trials. Cancer Treat. Rev. 2015, (in press).
6. Nazim S.M., Abbas F. Role of surgery in locally advanced prostate cancer. Pak. J. Med. Sci. 2015, 31:710-716.
7. Faria E.F., Chapin B.F., Muller R.L., Machado R.D., Reis R.B., Matin S.F. Radical prostatectomy for locally advanced prostate cancer: current status. Urology 2015, 86:10-15.
8. Sommariva S., Tarricone R., Lazzeri M., Ricciardi W., Montorsi F. Prognostic value of the cell cycle progress ion score in patients with prostate cancer: a systematic review and meta-analysis. Eur. Urol. 2016, 69(1):107-115.
9. Cuzick J., Stone S., Fisher G., Yang Z.H., North B.V., Berney D.M., Beltran L., Greenberg D., Møller H., Reid J.E., Gutin A., Lanchbury J.S., Brawer M., Scardino P. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br. J. Cancer 2015, 113(3):382-389.
10. Freedland S.J., Gerber L., Reid J., Welbourn W., Tikishvili E., Park J., Younus A., Gutin A., Sangale Z., Lanchbury J.S., Salama J.K., Stone S. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2013, 86:848-853.
11. Li C., Lin M., Liu J. Identification of PRC1 as the p53 target gene uncovers a novel function of p53 in the regulation of cytokinesis. Oncogene 2004, 23:9336-9347.
12. Lin Z.Y., Huang Y.Q., Zhang Y.Q., Han Z.D., He H.C., Ling X.H., Fu X., Dai Q.S., Cai C., Chen J.H., Liang Y.X., Jiang F.N., Zhong W.D., Wang F., Wu C.L. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. Int. J. Cancer 2014, 135:541-550.
13. Chen G., Liang Y.X., Zhu J.G., Fu X., Chen Y.F., Mo R.J., Zhou L., Fu H., Bi X.C., He H.C., Yang S.B., Wu Y.D., Jiang F.N., Zhong W.D. CC chemokine ligand 18correlates with malignant progression of prostate cancer. Biomed. Res. Int. 2014, 2014:230183.
14. Esfahani M., Ataei N., Panjehpour M. Biomarkers for evaluation of prostate cancer prognosis. Asian Pac. J. Cancer Prev. 2015, 16:2601-2611.
15. Pathak S.K., Sharma R.A., Steward W.P., Mellon J.K., Griffiths T.R., Gescher A.J. Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. Eur. J. Cancer 2005, 41:61-70.
16. Jiang W., Jimenez G., Wells N.J., Hope T.J., Wahl G.M., Hunter T., Fukunaga R. PRC1: a human mitotic spindle-associated CDK substrate protein required for cytokinesis. Mol. Cell 1998, 2:877-885.
17. Tang H., Xiao G., Behrens C., Schiller J., Allen J., Chow C.W., Suraokar M., Corvalan A., Mao J., White M.A., Wistuba I.I., Minna J.D., Xie Y. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin. Cancer Res. 2013, 19:1577-1586.
18. Felty Q., Singh K.P., Roy D. Estrogen-induced G1/S transition of G0-arrested estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signaling. Oncogene 2005, 24:4883-4893.
19. Mustacchi G., Sormani M.P., Bruzzi P., Gennari A., Zanconati F., Bonifacio D., Monzoni A., Morandi L. Identification and validation of a new set of five genes for prediction of risk in early breast cancer. Int. J. Mol. Sci. 2013, 14:9686-9702.
20. Kanehira M., Katagiri T., Shimo A., Takata R., Shuin T., Miki T., Fujioka T., Nakamura Y. Oncogenic role of MPHOSPH1: a cancer-testis antigen specific to human bladder cancer. Cancer Res. 2007, 67:3276-3285.